Shots: Oncology to evaluate Ixempra (ixabepilone) in combination with DRP CDx for metastatic breast cancer in EU. Post the results of trial, Oncology has an exclusive option to in-license commercialization […]readmore
Tags : Agreement
Shots: Sangamo has an option to access Brammer’s AAV manufacturing facility with 2000-L bioreactor scale used in development of gene therapies. Additionally, Sangamo has rights for Brammer’s viral vector manufacturing […]readmore
Shots: Merck exercises its option to extend its Feb,2015 agreement with NGM for development and commercialization of novel biologics therapies. NGM to receive $20M as an extension fee for R&D […]readmore
Shots: OliX to receive $2.27M upfront, clinical milestones and royalties on sales of product. Thea to get license rights to develop & commercialize OLX301A in EU, Middle East and Africa […]readmore
Shots: Cellesce & Hubrecht Organoid Technology (HUB) enters into an agreement for the expansion of breast organoids utilizing bioprocessing technology and HUB’s Organoid Technology at large scale The focus of […]readmore
Shots: Bill & Melinda Gates Foundation provides $4.8M fund to AbCellera to develop Ab for infectious diseases including HIV, malaria & tuberculosis The focus of the agreement is to get […]readmore
Shots: King’s and Wellcome to receive $340M as development and commercial milestone and royalties on sales. MSD to get a license for conducting lead optimization, preclinical & clinical research The […]readmore
Shots: With the closure of the transaction, Oncternal Therapeutics will be listed on Nasdaq under the ticker ONCT Oncternal’s stockholders will hold 75% of the shares of combined company and […]readmore
Shots: Akili to receive $20M upfront, $105M as development & commercialization milestones, making the total the deal value $125M & royalties on sales of the products. Shionogi to get exclusive […]readmore
Shots: ProMab Biotechnologies signs WW license agreement with NantKwest to develop Ab targeting B-Cell Maturation Antigen (BCMA) against myeloma ProMab Biotechnologies get an option to add five chimeric antigen receptor […]readmore